nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.06.2010

MicroRNA-21 in Cardiovascular Disease

verfasst von: Yunhui Cheng, Chunxiang Zhang

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches. Programmed cell death 4 (PDCD4), phosphatase and tensin homology deleted from chromosome 10 (PTEN), sprouty1 (SPRY1), and sprouty2 (SPRY2) are the current identified target genes of miR-21 that are involved in miR-21-mediated cardiovascular effects. miR-21 might be a novel therapeutic target in cardiovascular diseases. This review article summarizes the research progress regarding the roles of miR-21 in cardiovascular disease.

Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843–854.CrossRefPubMed

Wightman, B., Ha, I., & Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75(5), 855–862.CrossRefPubMed

Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of novel genes coding for small expressed RNAs. Science, 294(5543), 853–858.CrossRefPubMed

Friedman, J. M., & Jones, P. A. (2008). MicroRNAs: critical mediators of differentiation, development and disease. Swiss Medical Weekly, 139(33–34), 466–472.

Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., et al. (2005). Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genetics, 37(7), 766–770.CrossRefPubMed

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.CrossRefPubMed

Pushparaj, P. N., Aarthi, J. J., Kumar, S. D., & Manikandan, J. (2008). RNAi and RNAa—the yin and yang of RNAome. Bioinformation, 2(6), 235–237.PubMed

Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120(1), 15–20.CrossRefPubMed

Krichevsky, A. M., & Gabriely, G. (2009). miR-21: a small multi-faceted RNA. Journal of Cellular and Molecular Medicine, 13(1), 39–53.CrossRefPubMed

10.

Selcuklu, S. D., Donoghue, M. T., & Spillane, C. (2009). miR-21 as a key regulator of oncogenic processes. Biochemical Society Transactions, 37(Pt 4), 918–925.CrossRefPubMed

11.

Fujita, S., Ito, T., Mizutani, T., Minoguchi, S., Yamamichi, N., Sakurai, K., et al. (2008). miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. Journal of Molecular Biology, 378(3), 492–504.CrossRefPubMed

12.

Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735–739.CrossRefPubMed

13.

Zhang, C. (2008). MicroRNomics: a newly emerging approach for disease biology. Physiological Genomics, 33(2), 139–147.CrossRefPubMed

14.

Ji, R., Cheng, Y., Yue, J., Yang, J., Liu, X., Chen, H., et al. (2007). MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circulation Research, 100(11), 1579–1588.CrossRefPubMed

15.

Suarez, Y., Fernandez-Hernando, C., Pober, J. S., & Sessa, W. C. (2007). Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circulation Research, 100(8), 1164–1173.CrossRefPubMed

16.

Cheng, Y., Ji, R., Yue, J., Yang, J., Liu, X., Chen, H., et al. (2007). MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? American Journal of Pathology, 170(6), 1831–1840.CrossRefPubMed

17.

Roy, S., Khanna, S., Hussain, S. R., Biswas, S., Azad, A., Rink, C., et al. (2009). MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovascular Research, 82(1), 21–29.CrossRefPubMed

18.

Lin, Y., Liu, X., Cheng, Y., Yang, J., Huo, Y., & Zhang, C. (2009). Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. Journal of Biological Chemistry, 284(12), 7903–7913.CrossRefPubMed

19.

Oudit, G. Y., Sun, H., Kerfant, B. G., Crackower, M. A., Penninger, J. M., & Backx, P. H. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. Journal of Molecular and Cellular Cardiology, 37(2), 449–471.CrossRefPubMed

20.

Lankat-Buttgereit, B., & Göke, R. (2009). The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biology of the Cell, 101(6), 309–317.CrossRefPubMed

21.

Cheng, Y., Liu, X., Zhang, S., Lin, Y., Yang, J., & Zhang, C. (2009). MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. Journal of Molecular and Cellular Cardiology, 47(1), 5–14.CrossRefPubMed

22.

Cordes, K. R., Sheehy, N. T., White, M. P., Berry, E. C., Morton, S. U., Muth, A. N., et al. (2009). miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature, 460(7256), 705–710.PubMed

23.

Matsumoto, T., & Hwang, P. M. (2007). Resizing the genomic regulation of restenosis. Circulation Research, 100(11), 1537–1539.CrossRefPubMed

24.

Zhang, C. (2008). MicroRNAs: role in cardiovascular biology and disease. Clinical Science, 114(12), 699–706.CrossRefPubMed

25.

Sayed, D., Hong, C., Chen, I. Y., Lypowy, J., & Abdellatif, M. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Research, 100(3), 416–424.CrossRefPubMed

26.

van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 103(48), 18255–18260.CrossRefPubMed

27.

Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 13(5), 613–618.CrossRefPubMed

28.

Tatsuguchi, M., Seok, H. Y., Callis, T. E., Thomson, J. M., Chen, J. F., Newman, M., et al. (2007). Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology, 42(6), 1137–1141.CrossRefPubMed

29.

Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456(7224), 980–984.CrossRefPubMed

30.

Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., et al. (2007). MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation, 116(3), 258–267.CrossRefPubMed

31.

Dong, S., Cheng, Y., Yang, J., Li, J., Liu, X., Wang, X., et al. (2009). MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. Journal of Biological Chemistry, 284(43), 29514–29525.CrossRefPubMed

32.

Sayed, D., Rane, S., Lypowy, J., He, M., Chen, I. Y., Vashistha, H., et al. (2008). MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Molecular Biology of the Cell, 19(8), 3272–3282.CrossRefPubMed

33.

van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., et al. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 13027–13032.CrossRefPubMed

34.

Yin, C., Salloum, F. N., & Kukreja, R. C. (2009). A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circulation Research, 104(5), 572–575.CrossRefPubMed

35.

Yin, C., Wang, X., & Kukreja, R. C. (2008). Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia–reperfusion in mice. FEBS Letters, 582(30), 4137–4142.CrossRefPubMed

36.

Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005–1017.CrossRefPubMed

37.

Schulz, R. (2007). Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annual Review of Pharmacology and Toxicology, 47, 211–242.CrossRefPubMed

38.

Viappiani, S., Nicolescu, A. C., Holt, A., Sawicki, G., Crawford, B. D., León, H., et al. (2009). Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochemical Pharmacology, 77(5), 826–834.CrossRefPubMed

39.

Guo, H., Shi, Y., Liu, L., Sun, A., Xu, F., & Chi, J. (2009). Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Archives of Medical Research, 40(5), 345–351.CrossRefPubMed

40.

Thompson, M., & Cockerill, G. (2006). Matrix metalloproteinase-2: the forgotten enzyme in aneurysm pathogenesis. Annals of the New York Academy of Sciences, 1085, 170–174.CrossRefPubMed

41.

Pepper, M. S. (2001). Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 7, 1104–1117.CrossRef

42.

Ikeda, S., Kong, S. W., Lu, J., Bisping, E., Zhang, H., Allen, P. D., et al. (2007). Altered microRNA expression in human heart disease. Physiological Genomics, 31(3), 367–373.CrossRefPubMed

43.

Thum, T., Catalucci, D., & Bauersachs, J. (2008). MicroRNAs: novel regulators in cardiac development and disease. Cardiovascular Research, 79(4), 562–570.CrossRefPubMed

44.

Krutzfeldt, J., Poy, M. N., & Stoffel, M. (2006). Strategies to determine the biological function of microRNAs. Nature Genetics, 38, S14–19.CrossRefPubMed

45.

Cheng, A. M., Byrom, M. W., Shelton, J., & Ford, L. P. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Research, 33(4), 1290–1297.CrossRefPubMed

46.

Schroen, B., & Heymans, S. (2009). MicroRNAs and beyond: the heart reveals its treasures. Hypertension, 54(6), 1189–1194.CrossRefPubMed

Titel: MicroRNA-21 in Cardiovascular Disease
verfasst von: Yunhui Cheng
Chunxiang Zhang
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 3/2010
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-010-9169-7

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Toward Understanding the Informatics and Statistical Aspects of Micro-RNA Profiling

miRNAs as Therapeutic Targets in Ischemic Heart Disease

MicroRNAs—Regulators of Signaling Networks in Dilated Cardiomyopathy

Role of Specific MicroRNAs in Regulation of Vascular Smooth Muscle Cell Differentiation and the Response to Injury